GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others

GSK's Departure:
GlaxoSmithKline (GSK) has decided not to renew its membership with the Biotechnology Innovation Organization (BIO) for 2025, following an annual evaluation of its corporate memberships and trade associations34.

Recent Exits:
GSK's exit follows similar decisions by other major pharmaceutical companies, including Takeda, UCB, Pfizer, WuXi AppTec, and AbbVie, which have also left BIO over the past year14.

Industry Challenges:
The pharmaceutical industry faces an uncertain political future, particularly with the incoming Trump administration and ongoing legal challenges to the Inflation Reduction Act's drug price negotiation program4.

Legal Battles:
Pharmaceutical companies have been arguing that the drug price negotiation program is unconstitutional, citing violations of the Fifth and First Amendments, but courts have largely been skeptical, with several companies losing their cases4.

BIO's Response:
BIO has expressed disappointment over the departures but maintains that its mission to protect patients and medical innovation in the United States remains unaffected4.

Sources:

1. https://cafepharma.com/boards/threads/gsk-calls-it-quits-on-trade-group-bio-for-2025-following-exits-by-takeda-ucb-and-more.704578/

3. https://www.fiercepharma.com/pharma/gsk-calls-it-quits-trade-group-bio-2025-following-exits-takeda-ucb-and-more

4. https://www.biospace.com/business/gsk-quits-trade-group-bio-as-industry-faces-uncertain-political-future